{
  "meta": {
    "title": "Recent_Updates_Mini_Test",
    "url": "https://brainandscalpel.vercel.app/recent-updates-mini-test-d50332fe.html",
    "scrapedAt": "2025-11-30T12:47:12.240Z"
  },
  "questions": [
    {
      "text": "1. Which of the following is the new FDA-approved oral medication for the treatment of Niemann-Pick disease, type C (NPC)?",
      "choices": [
        {
          "id": 1,
          "text": "Edaravone"
        },
        {
          "id": 2,
          "text": "Arimoclomol"
        },
        {
          "id": 3,
          "text": "Amifampridine"
        },
        {
          "id": 4,
          "text": "Vonoprazan"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Arimoclomol, in combination with the enzyme inhibitor miglustat, is the new FDA-approved oral medication to treat neurological symptoms associated with Niemann-Pick disease, type C (NPC) in adults and children 2 years of age and older.<br><br>Arimoclomol (Miplyffa) is the first drug approved by the FDA to treat NPC. It is a rare genetic disease that results in progressive neurological symptoms and organ dysfunction. It is caused by changes in either the NPC1 or NPC2 gene, affecting the necessary transport of cholesterol and other lipids within a cell.<br><br>Other Options:<br><br>Option A: Edaravone is a free-radical scavenger newly approved for use in amyotrophic lateral sclerosis (ALS).<br><br>Option C: Amifampridine is a voltage-gated potassium channel blocker used to treat Lambert-Eaton myasthenic syndrome.<br><br>Option D: Vonoprazan is the new FDA-approved potassium-competitive acid blocker used for the management of erosive esophagitis.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "2. Which of the following is not a part of the lab criteria for diagnosis of APLA syndrome?<br><br>aPTT- Activated Partial Thromboplastin Time",
      "choices": [
        {
          "id": 1,
          "text": "Presence of lupus anticoagulant"
        },
        {
          "id": 2,
          "text": "Raised aPTT"
        },
        {
          "id": 3,
          "text": "Anticardiolipin antibodies"
        },
        {
          "id": 4,
          "text": "Anti-β2 glycoprotein antibody"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Raised aPTT is not a lab criterion for the diagnosis of antiphospholipid antibody (APLA) syndrome. <br><br>Antiphospholipid antibody syndrome is an autoimmune disorder that is commonly associated with fetal death, preterm delivery, early-onset preeclampsia, and fetal growth restriction due to placental insufficiency and thromboses. Pregnancy loss usually occurs before 10 weeks.<br><br>Diagnosis of APLA requires at least 1 clinical criterion and 1 laboratory criterion.<br><br>* Obstetric criteria<br><br>* One or more unexplained deaths of a morphologically normal fetus at or beyond 10 weeks, or<br><br>* Severe preeclampsia or placental insufficiency requiring delivery before 34 weeks, or<br><br>* Three or more unexplained consecutive spontaneous abortions before 10 weeks<br><br>* Laboratory criteria<br><br>* Presence of lupus anticoagulant, or<br><br>* Anticardiolipin antibodies, or<br><br>* Anti-β2 glycoprotein antibody<br><br>Recurrent pregnancy loss (RPL), also referred to as a recurrent miscarriage or habitual abortion, is historically defined as 3 consecutive pregnancy losses before 20 weeks from the last menstrual period. <br><br>Note: The new 2023 ACR/EULAR criteria is an update from the revised Sapporo criteria, with the clinical criteria divided into 6 domains and each metric in the clinical and laboratory value adding a weighted score. This has increased the specificity in diagnosing APS.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "3. An 18-year-old girl who was diagnosed with SLE at 13 years of age is now refractory to standard treatment. She is prescribed a monoclonal antibody which is an anti-B-cell activator. Which of the following drugs is she prescribed?",
      "choices": [
        {
          "id": 1,
          "text": "Rozanolixizumab"
        },
        {
          "id": 2,
          "text": "Belimumab"
        },
        {
          "id": 3,
          "text": "Daclizumab"
        },
        {
          "id": 4,
          "text": "Adalimumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Belimumab is a monoclonal antibody that is an anti-B-cell activator. It is used in the management of lupus refractory to standard treatment. <br><br>Belimumab targets the soluble B cell survival factor (BLyS or BAFF), inhibiting its action, which otherwise supports memory B cell development and autoantibody production. It is used in combination with either cyclophosphamide or MMF in patients with lupus nephritis who do not show a response to initial therapy with steroids.<br><br>Other options:<br><br>Option A: Rozanolixizumab is a humanized IgG4 monoclonal antibody that has been recently FDA-approved for the treatment of myasthenia gravis.<br><br>Option C: Daclizumab is an IL2R antagonist that binds to CD25 and is used in the relapsing type of multiple sclerosis.<br><br>Option D: Adalimumab is an anti-TNF alpha agent used in the treatment of rheumatoid arthritis.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "4. A middle-aged patient with obesity and elevated liver enzymes is diagnosed with nonalcoholic steatohepatitis (NASH). Which of the following is a newly approved drug for the treatment of NASH with moderate to advanced liver scarring?",
      "choices": [
        {
          "id": 1,
          "text": "Elafibranor"
        },
        {
          "id": 2,
          "text": "Vamorolone"
        },
        {
          "id": 3,
          "text": "Obeticholic acid"
        },
        {
          "id": 4,
          "text": "Resmetirom"
        }
      ],
      "correct_choice_id": 4,
      "solution": "Resmetirom (brand name REZDIFFRA) is indicated for the treatment of adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis in conjunction with diet and exercise.<br><br>It is a selective thyroid hormone receptor (THR)-beta agonist. It acts primarily in the liver, where THR-beta is the predominant form of thyroid hormone receptor. Activation of THR-beta by resmetirom reduces intrahepatic triglycerides and liver fat content. This selective activation minimizes the effects of THR-alpha, which mediates thyroid hormone actions in the heart and bone.<br><br>Common adverse effects include gastrointestinal symptoms such as diarrhoea, nausea, vomiting, constipation, and abdominal pain. Hepatotoxicity and gallbladder-related adverse reactions are significant concerns.<br><br>Other options:<br><br>Option A. Elafibranor is a medication used for the treatment of primary biliary cholangitis. It is a dual PPARα/δ agonist.<br><br>Option B. Vamorolone is a synthetic corticosteroid, which is used for the treatment of Duchenne muscular dystrophy. <br><br>Option C. Obeticholic acid is used to treat primary biliary cholangitis.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "5. A 60-year-old man who is a current smoker with COPD & chronic bronchitis experiences symptoms despite being on a LABA+LAMA. His blood eosinophil count is 300 cells/μL. Which of the following is the next line of management for him?<br><br>LABA - Long-acting beta agonist<br><br>LAMA - Long-acting muscarinic antagonists",
      "choices": [
        {
          "id": 1,
          "text": "Add inhaled corticosteroids"
        },
        {
          "id": 2,
          "text": "Add Azithromycin"
        },
        {
          "id": 3,
          "text": "Add Roflumilast"
        },
        {
          "id": 4,
          "text": "Add systemic corticosteroids"
        }
      ],
      "correct_choice_id": 1,
      "solution": "For a patient who is a smoker with COPD who experiences symptoms despite being on LABA+LAMA with a blood eosinophil count > 300 cells/μL, the next line of management would be adding inhaled corticosteroids (ICS).<br><br>According to the latest GOLD 2024 guidelines for the management of COPD exacerbations:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/71d1e879908748bc9ac4aa39c09ce780x1280x1807.JPEG\" alt=\"Explanation Image\"><br><br>Other options:<br><br>Option B: Adding azithromycin would be the next step for someone who is a former smoker on LABA+ LAMA + ICS with exacerbations.<br><br>Option C: Adding roflumilast would be the next step for someone who is a current smoker with chronic bronchitis on LABA+ LAMA + ICS with exacerbations.<br><br>Option D: Adding systemic steroids is not recommended in long-term management due to their side effects",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "6. Which of the following color-coded kits is recommended for the syndromic management of patients with anorectal discharge in sexually transmitted infections (STIs)?",
      "choices": [
        {
          "id": 1,
          "text": "Brown"
        },
        {
          "id": 2,
          "text": "Green"
        },
        {
          "id": 3,
          "text": "White"
        },
        {
          "id": 4,
          "text": "Blue"
        }
      ],
      "correct_choice_id": 1,
      "solution": "Kit 8 / Brown kit is recommended for the syndromic management of patients presenting with anorectal discharge.<br><br>NACO color-coded kits for syndromic management of STIs:<br><br><table>\n<tbody>\n<tr>\n<td><span class=\"UIgfsOnl\">Kit</span></td>\n<td><span class=\"aclmXqZu\">Synd</span><span class=\"SFfVqUpN\">rome</span><span class=\"FuiJJLwM\">/s</span></td>\n</tr>\n<tr>\n<td><span class=\"futboTUY\">Kit</span> <span class=\"ZfOiMAeu\">1</span> <span class=\"duzBsIOL\">(Gre</span><span class=\"EujXwOvX\">y)</span></td>\n<td>\n<p><span class=\"ctwcdpEi\">Uret</span><span class=\"ekEKMOSK\">hr</span><span class=\"kdmukgiD\">al</span> <span class=\"WcINBJOt\">disc</span><span class=\"QThsdxHP\">harg</span><span class=\"pmJsPCoo\">e</span></p>\n<p><span class=\"swFgBKxt\">Cerv</span><span class=\"ombrUckC\">ical</span> <span class=\"futboTUY\">disc</span><span class=\"idPNDhUV\">harg</span><span class=\"IRwtCkHY\">e</span></p>\n<p><span class=\"NgKdDrde\">Pai</span><span class=\"FLjZthyX\">nfu</span><span class=\"FLjZthyX\">l</span> <span class=\"nbmAhcKZ\">scr</span><span class=\"xkptDMpi\">otal</span> <span class=\"pvZwtHVr\">swe</span><span class=\"pSlLIXqT\">llin</span><span class=\"nbmAhcKZ\">g</span></p>\n</td>\n</tr>\n<tr>\n<td><span class=\"ibeSfDmH\">Kit</span> <span class=\"KblePVKX\">2</span> <span class=\"JfQypMYE\">(Gre</span><span class=\"KblePVKX\">en)</span></td>\n<td><span class=\"hCrNbswB\">Vagi</span><span class=\"CjGJTcVl\">nal</span> <span class=\"aclmXqZu\">disc</span><span class=\"ozdUOWTt\">ha</span><span class=\"hKPqMUWc\">rge</span> <span class=\"HqMoGMio\">/</span> <span class=\"kPAKLdWs\">Va</span><span class=\"nUkrFVLY\">gini</span><span class=\"inGOALgC\">tis</span></td>\n</tr>\n<tr>\n<td><span class=\"WcINBJOt\">Kit</span> <span class=\"SmitkxAG\">3</span> <span class=\"oDRXsbkb\">(W</span><span class=\"SJirFZrp\">hit</span><span class=\"twpWvacZ\">e)</span></td>\n<td><span class=\"TPUkKacO\">Non-</span><span class=\"PQGfMzrU\">he</span><span class=\"xQrYhcvb\">rp</span><span class=\"pvZwtHVr\">etic</span> <span class=\"pmJsPCoo\">ge</span><span class=\"twpWvacZ\">nita</span><span class=\"eOyIBYsW\">l</span> <span class=\"IxvezQfe\">ulce</span><span class=\"UIgfsOnl\">rs</span></td>\n</tr>\n<tr>\n<td><span class=\"JfQypMYE\">Kit</span> <span class=\"lCNPYkTL\">4</span> <span class=\"jhfmtKWo\">(Blu</span><span class=\"kmboNgwq\">e)</span></td>\n<td>\n<p><span class=\"HcsgpkTN\">Non</span><span class=\"HqMoGMio\">-h</span><span class=\"ZcVJWZYT\">erp</span><span class=\"PQGfMzrU\">et</span><span class=\"NgKdDrde\">ic</span> <span class=\"duzBsIOL\">ge</span><span class=\"xkptDMpi\">ni</span><span class=\"IcbsPOXV\">tal</span> <span class=\"PQGfMzrU\">ulce</span><span class=\"hvvCSOcA\">rs</span> <span class=\"WcINBJOt\">if</span> <span class=\"LrDoXylU\">all</span><span class=\"HqMoGMio\">er</span><span class=\"ctwcdpEi\">gic</span> <span class=\"yUJZMdMJ\">to</span> <span class=\"lCNPYkTL\">peni</span><span class=\"BlCOTHmt\">cill</span><span class=\"BlCOTHmt\">in</span></p>\n</td>\n</tr>\n<tr>\n<td><span class=\"yUJZMdMJ\">Kit</span> <span class=\"SLsiJwqD\">5</span> <span class=\"WcINBJOt\">(Re</span><span class=\"swFgBKxt\">d)</span></td>\n<td><span class=\"GugQstBo\">Herp</span><span class=\"IxvezQfe\">et</span><span class=\"EMLgGDNg\">ic</span> <span class=\"rcojiDHK\">geni</span><span class=\"xQrYhcvb\">tal</span> <span class=\"XcofbUqX\">ulc</span><span class=\"nbmAhcKZ\">er</span><span class=\"pmJsPCoo\">s</span></td>\n</tr>\n<tr>\n<td><span class=\"UcfxfMRx\">Kit</span> <span class=\"futboTUY\">6</span> <span class=\"ZfOiMAeu\">(Yel</span><span class=\"ZfOiMAeu\">low)</span></td>\n<td><span class=\"jhfmtKWo\">Lowe</span><span class=\"GJOTeBVm\">r</span> <span class=\"FLjZthyX\">abdo</span><span class=\"UEJSmTkE\">mina</span><span class=\"lCNPYkTL\">l</span> <span class=\"HqMoGMio\">pai</span><span class=\"futboTUY\">n</span></td>\n</tr>\n<tr>\n<td><span class=\"nwUShKwo\">Kit</span> <span class=\"rTilAgHp\">7</span> <span class=\"pSlLIXqT\">(Bla</span><span class=\"pvZwtHVr\">ck</span><span class=\"gbmIvCey\">)</span></td>\n<td><span class=\"iSCruWSK\">Ing</span><span class=\"SFfVqUpN\">uina</span><span class=\"SrBMSnhW\">l</span> <span class=\"CjGJTcVl\">bubo</span></td>\n</tr>\n<tr>\n<td><strong><span class=\"IcbsPOXV\">Kit</span> <span class=\"xkptDMpi\">8</span> <span class=\"SmitkxAG\">(B</span><span class=\"ekEKMOSK\">rown</span><span class=\"ekEKMOSK\">)</span></strong></td>\n<td><strong><span class=\"gCkwJJUd\">Anor</span><span class=\"wMDqXkTW\">ecta</span><span class=\"hCrNbswB\">l</span> <span class=\"UEJSmTkE\">di</span><span class=\"eOyIBYsW\">sc</span><span class=\"LzxGhhaS\">harg</span><span class=\"TPUkKacO\">e</span> <span class=\"gbmIvCey\">synd</span><span class=\"uNGFBEqV\">ro</span><span class=\"nUkrFVLY\">me</span></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM2024: Syndromic Management of Sexually Transmitted Infections<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1167210a9cd6434a905a98bc64668d41x1280x2612.PNG\" alt=\"Explanation Image\"><br><br>Partner Management when asymptomatic is not required for Gardenella vaginalis, Candida and Herpes infections.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "7. Which of the following drugs delay the onset of Stage-3 in patients with Stage-2 of Type 1 Diabetes?",
      "choices": [
        {
          "id": 1,
          "text": "Omaveloxolone"
        },
        {
          "id": 2,
          "text": "Teplizumab"
        },
        {
          "id": 3,
          "text": "Insulin"
        },
        {
          "id": 4,
          "text": "Erenumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Teplizumab is a recently approved drug used to delay the onset of Stage 3 in patients with Stage 2 of Type 1 Diabetes Mellitus(Type 1 DM).<br><br>Type 1 DM is caused due to immune-mediated destruction of the pancreatic beta cells and insulin deficiency. Patients usually present in adolescence or early adulthood with classical features of DM. Based on further evaluation, patients with Type 1 DM can be further categorised into three stages.<br><br>Stage 1 disease is characterized by the development of two or more islet cell autoantibodies but the maintenance of normoglycemia. Stage 2 disease is defined by continued autoimmunity and the development of dysglycemia(due to progressive beta-cell destruction). Stage 3 is defined by the development of hyperglycemia that exceeds the diagnostic criteria for the diagnosis of diabetes.<br><br>Teplizumab is a new drug that can delay the onset of Stage 3 of Type 1 DM in patients with Stage 2 of Type 1 DM. It acts by binding to CD-3 of T cells and possibly does partial agonistic signalling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Thus, the progressive destruction of beta cells in the pancreas is delayed. The adverse effects of the drug include lymphopenia and severe infections, rash, hypersensitivity reactions, and headache.<br><br>Other Options:<br><br>Option A: Omaveloxolone is an activator of Nrf2, a newly FDA-approved drug for the treatment of Friedrich’s ataxia.<br><br>Option C: Insulin is the drug of choice in patients with Type 1 DM, but it does not affect the disease progression.<br><br>Option D: Erenumab is a CGRP receptor antagonist used in the treatment of an acute attack of migraine.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "8. Which of the following drugs has been recently approved by the FDA for treating moderate to severe obstructive sleep apnea in adults with obesity and works through this mechanism?",
      "choices": [
        {
          "id": 1,
          "text": "Semaglutide"
        },
        {
          "id": 2,
          "text": "Teduglutide"
        },
        {
          "id": 3,
          "text": "Tirezepatide"
        },
        {
          "id": 4,
          "text": "Repaglinide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Tirzapatide is recently approved by the FDA for treating moderate to severe obstructive sleep apnea in adults with obesity.<br><br>It is a dual GIP/GLP-1 receptor agonist that was previously approved for the management of type 2 diabetes and for chronic weight management in adults who have a BMI of 27kg/m^2 or greater with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).<br><br>Other options :<br><br>Option A: Semaglutide is a GLP-1 agonist that was recently approved as a subcutaneous injection once weekly for chronic weight management.<br><br>Option B: Teduglutide is a GLP2 analogue approved for the management of Short Bowel syndrome.<br><br>Option D: Repaglinide acts by increasing insulin secretion by blockage of ATP-sensitive K+ channels of the beta cells of the pancreas.",
      "explanation_video": "",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/4562899409e9431ba537f8532439a803.PNG"
      ],
      "explanation_images": []
    },
    {
      "text": "9. A 40-year-old woman, who presented with a thyroid nodule was advised to undergo FNAC. The cytology report classifies the nodule as Bethesda category 4. What would be the usual management in this case?",
      "choices": [
        {
          "id": 1,
          "text": "Clinical follow-up"
        },
        {
          "id": 2,
          "text": "Lobectomy"
        },
        {
          "id": 3,
          "text": "Repeat FNAC"
        },
        {
          "id": 4,
          "text": "Total thyroidectomy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The usual management of a patient classified as Bethesda category 4 is Lobectomy. <br><br>Fine-needle aspiration cytology (FNAC) of the thyroid is the initial screening test for thyroid nodules. The Bethesda system classifies thyroid FNAC into six categories. Each category is linked to a malignancy risk and has a recommended clinical management. <br><br>Bethesda criteria for reporting thyroid cytopathology:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f5ed1c1acee94af1aaa98a1c96fb38fbx1280x1698.JPEG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "10. A woman was drugged with ketamine which was slipped into her drink without her knowledge by a stranger, intending to harm her. Her friends noticed that she was drugged and other eyewitnesses in the bar helped in apprehending the perpetrator. The accused is punishable under which section of the BNS?<br><br>BNS- Bharatiya Nayaya Sanhita; IPC- Indian Penal Code",
      "choices": [
        {
          "id": 1,
          "text": "BNS Sec 118(1) (324 IPC)"
        },
        {
          "id": 2,
          "text": "BNS Sec 123 (328 IPC)"
        },
        {
          "id": 3,
          "text": "BNS Sec 118(2) (326 IPC)"
        },
        {
          "id": 4,
          "text": "BNS Sec 286 (284 IPC)"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The given clinical scenario of a person poisoning another person with a stupefying drug is punishable under BNS Sec 123 (328 IPC).<br><br>BNS Sec 123 (328 IPC) states that whoever administers to or causes to be taken by any person, any poison or any stupefying, intoxicating or unwholesome drug, or any other thing with intent to cause hurt to such person, or with intent to commit or to facilitate the commission of an offense, shall be punished with imprisonment up to ten years and also fine.<br><br>Other options:<br><br>BNS Sec 118(1) (324 IPC) - Voluntarily causing hurt by dangerous means. This section states that whoever volun­tarily causes hurt by means of any poison or any corrosive substance shall be punished with imprisonment for a term which may extend to three years, or with fine, or with both.<br><br>BNS Sec 118(2) (326 IPC) - Voluntarily causing grievous hurt by dangerous means. Offenders who voluntarily cause grievous hurt by means of any poison or any corrosive substance shall be pun­ished with imprisonment for life, or with imprisonment for a term which may extend to ten years, and shall also be liable to fine.<br><br>BNS Sec 286 (284 IPC)- deals with 'Negligent conduct with respect to poisonous substance' - It states that whoever does, with any poisonous substance, any act in a manner so rash or negligent as to endanger human life, or to be likely to cause hurt or injury to any person, or knowingly, shall be punished with imprisonment for a term which may extend to six months, or with fine which may extend to five thousand rupees, or with both.<br><br>Date rape: Sexual intercourse with a woman after sedating her.<br><br>Common date rape drugs include:<br><br>* Gamma-hydroxybutyrate (GHB)<br><br>* Gamma-butyrolactone (GBL)<br><br>* Rohypnol (flunitrazepam)<br><br>* Ketamine",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "11. Which of the following are major criteria to diagnose infective endocarditis?<br><br>* Phase I IgG antibody titer for Coxiella >1:800<br><br>* Single positive blood culture for coagulase-negative Staphylococci<br><br>* New onset valvular regurgitation<br><br>* IV drug abuse<br><br>* Janeway lesions",
      "choices": [
        {
          "id": 1,
          "text": "2, 4, 5"
        },
        {
          "id": 2,
          "text": "3, 4"
        },
        {
          "id": 3,
          "text": "1, 2, 3"
        },
        {
          "id": 4,
          "text": "1, 3"
        }
      ],
      "correct_choice_id": 4,
      "solution": "Phase I IgG antibody titer >1:800 for Coxiella and new onset valvular regurgitation are major criteria in the Modified Duke criteria for infective endocarditis.<br><br>Single positive blood culture for coagulase-negative Staphylococci (statement 2) is likely to be due to contamination of the blood culture sample during sample collection. One set of samples taken for infective endocarditis consists of 2 bottles of blood culture (one for aerobic and one for anaerobic culture).<br><br>Three such sets are taken from different venipuncture sites over 1-2 hours. At least two of these cultures have to be positive for the positive blood culture criteria to be considered positive in the Duke criteria. Antibody titers to Coxiella are included in the major criteria because it is difficult to recover the organism by blood culture.<br><br>Predisposing factors such as IV drug abuse (statement 4) and certain congenital heart diseases and vascular phenomena such as Janeway lesions are included in the minor criteria.<br><br>Pearl PM2026: Modified Duke's criteria for diagnosis of infective endocarditis<br><br>Diagnosis of Infective endocarditis is by Duke's Criteria, which requires either:<br><br>* Pathologic criteria<br><br>* Clinical criteria<br><br>If clinical criteria are used, definitive endocarditis is defined by the presence of 2 major or 1 major + 3 minor or 5 minor criteria.<br><br>The presence of single pathological criteria is definitive of infective endocarditis. <br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/186ed21749ed4d3ab7e43344abb39a78x1200x2770.JPEG\" alt=\"Explanation Image\"><br><br>Note: The diagnosis of endocarditis is rejected if an alternative diagnosis is established either when:<br><br>* Symptoms resolve and do not recur with <4 days of antibiotic therapy OR<br><br>* If surgery or autopsy yields no pathologic or macroscopic evidence of endocarditis in <4 days of antimicrobial therapy.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "12. Actalycabtagene autoleucel was recently approved in India to treat B cell lymphoma. It works by modifying the patient’s own immune cells using a viral vector and reinfusing them to specifically target cancer cells. What is the name of this therapy?",
      "choices": [
        {
          "id": 1,
          "text": "Checkpoint inhibitor therapy"
        },
        {
          "id": 2,
          "text": "Bispecific T-cell engager (BiTE) therapy"
        },
        {
          "id": 3,
          "text": "Chimeric antigen receptor (CAR) T-cell therapy"
        },
        {
          "id": 4,
          "text": "Oncolytic virus therapy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Actalycabtagene autoleucel, is a form of chimeric antigen receptor (CAR) T-cell therapy that has been recently approved in India as NexCAR19 to treat B-cell lymphoma and B-acute lymphoblastic leukaemia. <br><br>In this treatment, a patient's own T-cells are genetically modified using a viral vector to express a chimeric antigen receptor that specifically targets cancer cells. These modified T-cells are then reinfused into the patient, where they can recognize and destroy cancer cells expressing the target antigen. CAR T-cell therapy has shown promising results in treating certain types of B cell lymphoma by harnessing the patient's own immune system to fight cancer.<br><br>Other options: <br><br>Option A: Checkpoint inhibitor therapy, involves the use of drugs that block immune checkpoints to enhance the immune system's ability to recognize and attack cancer cells. <br><br>Option B: Bispecific T-cell engager (BiTE) therapy, utilizes synthetic antibodies to redirect a patient's T-cells to target cancer cells. While BiTE therapy is another form of immunotherapy, it does not involve the modification of a patient's own T-cells.<br><br>Option D: Oncolytic virus therapy, uses genetically modified viruses to selectively infect and destroy cancer cells.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "13. A 35-year-old patient with moderate to severely active ulcerative colitis is being considered for treatment with a newly FDA-approved monoclonal antibody. This drug works by blocking the action of IL-23, a proinflammatory cytokine. Which of the following drugs is most likely being prescribed?",
      "choices": [
        {
          "id": 1,
          "text": "Mirikizumab"
        },
        {
          "id": 2,
          "text": "Infliximab"
        },
        {
          "id": 3,
          "text": "Golimumab"
        },
        {
          "id": 4,
          "text": "Adalimumab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "Mirikizumab is a monoclonal antibody that works by blocking the action of IL-23, a proinflammatory cytokine. It has recently received FDA approval for the treatment of moderate to severely active ulcerative colitis in adults.<br><br>Mirikizumab has shown significant benefits in clinical trials, including reduced rectal bleeding, stool frequency, and bowel urgency. Infliximab, Golimumab, and Adalimumab all belong to the class of TNF-alpha inhibitors. They work by binding to and neutralizing TNF-alpha, another proinflammatory cytokine involved in the pathogenesis of various autoimmune diseases, including ulcerative colitis. <br><br>Other biological drugs used in the treatment of inflammatory bowel disease:<br><br>Anti-TNF therapies:<br><br>* Infliximab<br><br>* Adalimumab<br><br>* Certolizumab<br><br>Anti-integrins:<br><br>* Natalizumab<br><br>* Vedolizumab<br><br>Note: Mirikizumab has also been approved for the treatment of moderate to severe Crohn's disease.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "14. Daprodustat, a newly approved drug is used in the treatment of which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Open Angle Glaucoma"
        },
        {
          "id": 2,
          "text": "Anemia in CKD patients"
        },
        {
          "id": 3,
          "text": "Postpartum hemorrhage"
        },
        {
          "id": 4,
          "text": "Gout"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Daprodustat is a newly approved drug by the FDA used for treating anemia in CKD patients.<br><br>In patients with CKD(Chronic Kidney Disease), there is decreased erythropoietin production, which in turn leads to the development of anemia.<br><br>Daprodustat is a reversible inhibitor of HIF-PH(Hypoxia-inducible factor–prolyl hydroxylase domain). This activity results in the stabilization and nuclear accumulation of HIF transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin, and thereby correcting anemia. However, an optimal response to treatment with Daprodustat occurs only when iron stores are adequate to complement the increased erythropoietin levels for producing new RBCs. It is reserved for patients who have been receiving dialysis for at least four months.<br><br>Daprodustat is given as a once-daily oral preparation. The most common adverse reactions are hypertension, thrombotic vascular events, and abdominal pain. It increases the risk of thrombotic vascular events, including major adverse cardiovascular events like myocardial infarction, stroke, and venous thromboembolism.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "15. Which of these is the drug recently approved by the FDA for complicated UTIs, including pyelonephritis?<br><br>UTI- Urinary tract infections",
      "choices": [
        {
          "id": 1,
          "text": "Dalfampridine"
        },
        {
          "id": 2,
          "text": "Cefepime-enmetazobactam"
        },
        {
          "id": 3,
          "text": "Ensifentrine"
        },
        {
          "id": 4,
          "text": "Obeticholic acid"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Cefepime-enmetazobactam, a combination of a fourth-generation cephalosporin and beta-lactamase inhibitor is the drug recently approved by the FDA for use in complicated UTIs (including pyelonephritis).<br><br>Other Options:<br><br>Option A- Dalfampridine is a broad-spectrum potassium channel blocker used in multiple sclerosis.<br><br>Option C: Ensifentrine is a dual (phosphodiesterase)PDE 3 and 4 inhibitor. It is an inhalational agent with combined effects on airway inflammation, bronchodilation, and ciliary function, making it a potent drug for maintenance treatment of COPD. <br><br>Option D: Obeticholic acid is used to treat primary biliary cholangitis.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "16. What is the current status of trachoma in India?",
      "choices": [
        {
          "id": 1,
          "text": "Eradicated from all states"
        },
        {
          "id": 2,
          "text": "Eliminated as a public health threat"
        },
        {
          "id": 3,
          "text": "Disease under control"
        },
        {
          "id": 4,
          "text": "Highly prevalent"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The World Health Organization has validated India as having eliminated trachoma as a public health problem in October 2024.<br><br>Trachoma is one of the leading causes of blindness globally. Though trachoma is preventable, blindness from trachoma is extremely difficult to reverse. Trachoma continues to be a public health problem in 39 countries and is responsible for the blindness of about 1.9 million people. In 2017, India was declared free from infective trachoma. As of October 2024, 21 countries, including India, have been validated by WHO as having eliminated trachoma as a public health problem.<br><br>Disease elimination is the complete interruption of the transmission of disease in a defined geographical area, but the causative organism may be persisting. This strategy works by trying to reduce the residual infection. <br><br>Disease eradication is the complete extermination of the organism.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "17. A 28-year old woman presents with symptoms of postpartum depression. Her physician decides to prescribe a newly FDA approved oral medication specifically for postpartum depression. Which medication is the physician most likely prescribing?",
      "choices": [
        {
          "id": 1,
          "text": "Brexanolone"
        },
        {
          "id": 2,
          "text": "Zuranolone"
        },
        {
          "id": 3,
          "text": "Escitalopram"
        },
        {
          "id": 4,
          "text": "Venlafaxine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Zuranolone is the first FDA-approved oral medication specifically for the treatment of postpartum depression. It works by modulating GABA receptors, providing rapid relief from depressive symptoms in postpartum women.<br><br>Postpartum depression is a type of mood disorder that occurs after childbirth, characterised by sadness, fatigue, changes in sleeping and eating patterns that start within 4 weeks as per DSM-5 or 6 weeks as per ICD-11, and persist for ≥ 2 weeks.<br><br>Management strategies include psychotherapy, social support, and medications. Selective serotonin reuptake inhibitors (SSRIs) are generally used off-label, but zuranolone offers a new FDA-approved option for oral treatment. <br><br>Other options:<br><br>Option A: Brexanolone is another FDA-approved treatment for postpartum depression, but it is administered intravenously. It increases serotonin levels in the brain, but typically takes longer to show effects compared to zuranolone<br><br>Option C: Escitalopram is an SSRI often prescribed off-label for postpartum depression, but it is not FDA-approved for this condition.<br><br>Option D: Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for the treatment of depression, but is not used in postpartum depression.<br><br>Pearl PM0497: Postpartum mood disorders<br><br><table>\n<tbody>\n<tr>\n<td><span><strong>Disorders and features</strong></span></td>\n<td><span><strong>Incidence and timeline</strong></span></td>\n<td><span><strong>Harmful thoughts</strong></span></td>\n<td><span><strong>Treatment</strong></span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Postpartum blues</strong>:</span></p>\n<p><span>Depressed affect, tearfulness and fatigue</span></p>\n</td>\n<td>\n<p><span>30-75%</span></p>\n<p><span>Starts 2-3 days after delivery. Resolves within 10 days.</span></p>\n</td>\n<td><span>No thoughts of harming the baby</span></td>\n<td><span>Support and follow up</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Postpartum depression</strong>:</span></p>\n<p><span>Depressed affect, anxiety, and poor concentration</span></p>\n</td>\n<td>\n<p><span>10-15%</span></p>\n<p><span>Starts within 4 weeks from delivery (DSM 5) or 6 weeks (ICD 11) and persists for ≥ 2 weeks. </span></p>\n</td>\n<td><span>Thoughts of harming the baby often present</span></td>\n<td><span>CBT and SSRIs </span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Postpartum psychosis</strong>:</span></p>\n<p><span>Mood-congruent delusions, hallucinations</span></p>\n</td>\n<td>\n<p><span>0.1-0.2%</span></p>\n<p><span>Onset within 4 weeks postpartum (DSM 5) or 6 weeks (ICD 11)</span></p>\n</td>\n<td><span>Thoughts of harming the baby or self</span></td>\n<td><span>Hospitalization, atypical antipsychotics and ECT for refractory cases</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Note: Zuranolone is the first-ever oral drug to be FDA-approved specifically for the treatment of postpartum depression. It is a neuroactive steroid that enhances the action of GABA in the brain and regulates mood.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "18. Which of the following drugs is approved for prophylaxis against respiratory syncytial virus (RSV) infection?",
      "choices": [
        {
          "id": 1,
          "text": "Ribavirin"
        },
        {
          "id": 2,
          "text": "Omalizumab"
        },
        {
          "id": 3,
          "text": "Nirsevimab"
        },
        {
          "id": 4,
          "text": "Oseltamivir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Nirsevimab is a monoclonal antibody recently approved by the FDA to be used as a prophylaxis against respiratory syncytial virus (RSV) infection.<br><br>RSV is responsible for more than half of the cases of bronchiolitis in infants less than 1 year of age. It generally presents as a fever with cough and wheezing. It has a very high infectivity, and transmission is by close contact and droplet transmission. Nasopharyngeal swabs and nasal washings are collected as samples. They are inoculated in cell culture (HeLa or Hep-2) immediately after collection. In cultured cells, RSV shows characteristic giant cells and syncytial formation.<br><br>The image given below shows giant cells and syncytial formation seen in RSV infection:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/06fa65cfa6304e6e8d0d2f9867d1bbadx1280x960.JPEG\" alt=\"Explanation Image\"><br><br>Nirsevimab is a monoclonal antibody with activity against RSV. One dose of Nirsevimab, administered as a single intramuscular injection prior to or during RSV season, may provide protection during the RSV season. Possible adverse effects include rash and injection site reactions.<br><br>Other options:<br><br>Option A: Ribavirin is used for treating RSV infections but is not approved for use as a prophylactic agent.<br><br>Option B: Omalizumab is a monoclonal antibody against IgE indicated in asthma.<br><br>Option D: Oseltamivir is used for the treatment of avian influenza and is not recommended to be used for RSV.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "19. Perfluorohexyloctane is used as:",
      "choices": [
        {
          "id": 1,
          "text": "An MRI contrast agent"
        },
        {
          "id": 2,
          "text": "A disinfectant in labs"
        },
        {
          "id": 3,
          "text": "A chemotherapy agent"
        },
        {
          "id": 4,
          "text": "A drug to manage dry eyes"
        }
      ],
      "correct_choice_id": 4,
      "solution": "Perfluorohexyloctane is a drug to manage dry eyes. <br><br>Dry eye disease occurs due to inadequate tear volume and function, resulting in unstable tear film and ocular surface disease. Many conditions can lead to dry eye, including sjögren syndrome, vitamin A deficiency, follicular conjunctivitis, usage of contact lenses, and trachoma. <br><br>Tear film tests (Schrimer's test, Tear film break up test, and Rose Bengal staining) are used to diagnose dry eye disease. Treatment for dry eye includes medical treatment (lubricating eyedrops, most commonly methylcellulose derivatives) or surgical treatment (lacrimal punctum occlusion using silicone plugs). <br><br>Recently, the FDA approved perfluorohexyloctane as an ophthalmic solution for treating dry eye. It is used as eyedrops to be instilled four times a day. It forms a monolayer at the tear film's air-liquid interface, which is expected to reduce evaporation. The most common adverse effect associated with the use of Perfluorohexyloctane is blurred vision.  Rarely, it can lead to conjunctival redness.<br><br>Pearl PM0801: Tear film tests used for the diagnosis of dry eye<br><br>Schirmer test<br><br>Inference <br><br>* 15 mm: Normal<br><br>* 5-10 mm: Moderate keratoconjunctivitis sicca (KCS)<br><br>* < 5 mm: Severe KCS<br><br>Tear film break up test (TBUT)<br><br>Inference <br><br>* 15-35 seconds: Normal<br><br>* < 10 seconds: Unstable tear film<br><br>Rose Bengal staining<br><br>Inference<br><br>* A pattern: Confluent staining → Severe KCS<br><br>* B pattern: Extensive staining → Moderate KCS<br><br>* C pattern: Fine punctate stains → Mild KCS<br><br>Tear osmolarity test<br><br>Abnormal osmolarity is defined by <br><br>* An elevated reading, >300 mOsm/L, indicating loss of homeostasis, or<br><br>* When the inter-eye difference is >8 mOsm/L, indicating instability of the tear film.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "20. As per the 2024 ESC Guidelines for Hypertension, what is the recommended blood pressure threshold for starting antihypertensive treatment in a diabetic patient with CKD, even after 3 months of lifestyle modifications?<br><br>CKD- Chronic Kidney Disease<br><br>ESC- European Society of Cardiology",
      "choices": [
        {
          "id": 1,
          "text": "≥ 130/80 mmHg"
        },
        {
          "id": 2,
          "text": "≥ 140/80 mmHg"
        },
        {
          "id": 3,
          "text": "≥ 130/ 90 mmHg"
        },
        {
          "id": 4,
          "text": "≥ 140/90 mmHg"
        }
      ],
      "correct_choice_id": 1,
      "solution": "As per the 2024 ESC Guidelines for Hypertension,≥ 130/80 mmHg is the recommended blood pressure threshold for starting antihypertensive treatment in a diabetic patient with CKD, even after 3 months of lifestyle modifications.<br><br>The 2024 ESC guidelines introduce key updates in the management of elevated blood pressure. While hypertension is defined as a blood pressure ≥140/90 mmHg, a new category of ‘elevated blood pressure’ has been introduced, which was defined as a systolic BP of 120- 139 mmHg or a diastolic BP of 70-89 mmHg.<br><br>The updated guidelines emphasise achieving a lower target BP across various disease groups. This shift represents a crucial step toward the timely prevention of cardiovascular risk progression associated with elevated blood pressure.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/180780a0aac24417824e8a8bd6160a1fx832x1609.JPEG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}